Table 2 Baseline characteristics of the study participants (n = 196)
Nottingham grade of cancer | Receptor status | ||
|---|---|---|---|
Low nuclear grade in situ CA | 01 (0.5%) | ER positives | 50 (25.5%) |
Grade I | 30 (15.3%) | PR positives | 38 (19.4%) |
Grade II | 101 (51.5%) | Her 2 positives | 02 (1.0%) |
Grade III | 64 (32.7%) | ER & PR positives | 94 (48.0%) |
Type of anthracycline | ER & Her 2 positives | 06 (3.1%) | |
Doxorubicin | 157 (80.1%) | PR & Her 2 positives | 03 (1.5%) |
Epirubicin | 39 (19.9%) | ER, PR & Her 2 positives | 03 (1.5%) |
Number of anthracycline cycles given | Other therapeutics used as the second part of the adjuvant programme | ||
04 cycles | 193 (98.5%) | None | 05 (2.6%) |
06 cycles | 03 (1.5%) | Docetaxel | 128 (65.3%) |
Patients with | Paclitaxel | 46 (23.4%) | |
Diabetes mellitus | 84 (42.9%) | Nano Paclitaxel | 17 (8.7%) |
Dyslipidaemia | 69 (35.2%) | Blood relatives | |
Neither 43 (21.9%) | With cancer | 47 (24.0%) | |
Marital status | Â | Without cancer | 149 (76.0%) |
Married | 148 (75.5%) | Â | |
Unmarried | 48 (24.5%) | Â | Â |